Ophtalmologie. Blocage des cytokines et chemokines: nouvelles perspectives de traitement [New therapies in ophthalmology: inhibitors of cytokines and chemokines: new treatment perspectives]
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_841E13D79990
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Ophtalmologie. Blocage des cytokines et chemokines: nouvelles perspectives de traitement [New therapies in ophthalmology: inhibitors of cytokines and chemokines: new treatment perspectives]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
12/01/2005
Peer-reviewed
Oui
Volume
1
Number
2
Pages
140-141
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Anti-TNF-alpha (infliximab and etanercept) are potent, selective inhibitors of the inflammatory cascade. They have been widely used in the therapy of rheumatoid arthritis, Crohn's disease and psoriasis. Their efficacy in ophthalmology has been recently proven. The wide use of cytokines inhibitors could also be very useful in the therapy of neovessels in macular degeneration age-related, since the role of inflammation in the proliferation of neovessels has been recently discovered.
Keywords
Chemokines/antagonists & inhibitors, Cytokines/antagonists & inhibitors, Eye Diseases/drug therapy, Humans, Tumor Necrosis Factor-alpha/antagonists & inhibitors
Pubmed
Create date
28/01/2008 14:10
Last modification date
18/04/2025 7:14
Usage data
